VVOTE'S THE SCIENCE OF WHAT'S POSSIBLE."

EMPOWER 2 METHOD VALIDATION MANAGER SOFTWARE: TOOL FOR RAPID METHOD VALIDATION

Daniel S. Root and Andrew J. Aubin Waters Corporation, Milford, MA, U.S.

INTRODUCTION

Within the compliant laboratory, the validation of analytical methods is a fact of life. Regulatory agencies must have documented evidence that the analytical methods employed by a laboratory yield accurate and reliable results. The laboratories, utilizing advanced planning and good scientific judgment, rely on validation as a means of assuring confidence in the results generated from their analytical methods. From both perspectives, there is no argument that analytical method validation is an important process and a permanent aspect of compliant laboratory operation.

Method validation is a demanding activity. It requires a large investment in personnel, materials, instruments, supervision, and, most of all, time. Some of the more time-consuming aspects of validation involve the creation of validation protocols and sample lists, tracking of the workflow from protocol to final reporting, the performance of calculations, and the intense need to organize and manage raw and processed data. The potential for errors in the many steps of the validation process is large and the time delay when errors occur can be costly.

Waters[®] Empower[™] 2 Method Validation Manager (MVM) Software, coupled with the Waters ACOUITY UPLC® System, can dramatically address these time-consuming elements of analytical method validation. The advantages of using the ACQUITY UPLC System have been reported previously. MVM is designed to streamline the set-up, execution, calculation, and reporting of a method validation. It provides easy data tracking and complete organization of validation data and results monitored by the built-in oversight of automated error checking. MVM is a business-critical software that reduces the time and costs required to perform chromatographic method validation by as much as 80%. Because MVM allows the entire chromatographic method validation process to be efficiently performed within Empower 2, fewer software applications need be deployed, validated, and maintained. Software training and support is also minimized. When less software is required, the software that is business-essential can be deployed more quickly and efficiently.

In addition, Method Validation Manager allows you to be fully compliant with governmental regulations by providing data security, a full set of user privileges, audit trails, and automatic data documentation; providing you with the necessary information and complete data traceability required for final reports and to pass audits and data reviews.

To illustrate the straightforward operation and comprehensive functionality of MVM, a basic assay validation of the drug product acetaminophen will be summarized. Multiple screenshots from MVM are presented with the validation results to help demonstrate the application of this software to the validation process.

EXPERIMENTAL

Materials

Acetaminophen RS was purchased from Sigma-Aldrich Co. (St. Louis, MO). Methanol was acquired from Fisher (Fair Lawn, NJ). Water was purified with a MilliQ Gradient A10 System (Millipore, Billerica, MA).

UPLC conditions

The assay was performed on a Waters ACQUITY UPLC System consisting of a Binary Solvent Manager (BSM), Sample Manager (SM), and Tunable UV Detector (TUV). A Waters ACQUITY UPLC BEH C_{18} , 1.7 μ m, 2.1 X 50 mm Column was selected for the separation. All instruments were controlled, and data were collected and analyzed, using Empower 2 Method Validation Manager Software.

Assay conditions

Mobile phase:	90:10 water/methanol, mixed by pump
Flow:	0.65 mL/min
Temperature:	40 °C
Injection volume:	1.0 μL
Wavelength:	243 nm
Runtime:	2 min
Retention time:	0.7 min

METHOD

Solution preparation

The acetaminophen working standard was made from a 1:9 dilution of a 0.1 mg/mL acetaminophen stock standard. 10 mg of acetaminophen RS was weighed accurately into a 100 mL volumetric flask, diluted to mark, and mixed with mobile phase. A 1.0 mL aliquot was then transferred to a 10 mL volumetric flask, diluted to mark, and mixed with mobile phase. The final concentration of the working standard was 0.01 mg/mL acetaminophen RS.

Acetaminophen sample preparation

Sample preparations for this method were made using the following procedure:

Weigh and finely powder at least 20 tablets. Transfer an accurately weighed portion, equivalent to about 100 mg of acetaminophen, to a 200 mL volumetric flask. Add approximately 100 mL of mobile phase and shake the solution for 10 minutes, then sonicate for 5 minutes. Fill the flask to mark with mobile phase.

Transfer a 5.0 mL aliquot of the above solution to a 250 mL volumetric flask, dilute to mark with mobile phase, and mix. The final concentration of this preparation should be approximately 0.01 mg/ mL acetaminophen.

Method system suitability criteria

The method system suitability criteria are listed in Table 1.

Parameter	Acceptance Criterion
%RSD RT min	≤ 1.0%
%RSD area acetaminophen in std	≤ 2.0%
USP tailing	≤ 1.5%
USP plates	≥ 1000

Table 1. Method suitability criteria.

Acetaminophen analysis with the ACQUITY UPLC System is shown in Figure 1.



Figure 1. Analysis of acetaminophen.

Validation protocol and execution

The elements of the written validation protocol for this method were easily transferred into the validation protocol method template of MVM (Figure 2). The following validation tests were performed in this study:

- Robustness (for three factors)
- Repeatability
- Intermediate precision (different analyst)
- Linearity
- Accuracy
- Solution stability (24 hours)

🥙 Validation Protocol - acetaminophen2 in dan root\WV	M_study\drug1_assayval\Amlodipine Assay	on INFM-EMPSRV-01 as roo	td/PowerUser - Validation Man 🔳 🗖 🔀
<u>File Edit View Tools H</u> elp			
Method Classification Compound Type: Drug Product Analytical Method Type: Assay Development Phase: Development Protocol Comments: Validation Tests System Precision Approvals/Sign Offs	Method/Study Approvals Validation Protocol Approval:		
Validation Tests			
🗑 Test Name	Test Description	Required	Test Status
1 Robustness	Robustness 1. 4 factors	v	Sample Sets Incomplete
2 Repeatability	Repeatability 1	V	Sample Sets Incomplete
3 Linearity	Linearity 1	V	Sample Sets Incomplete
4 Accuracy	Accuracy 1	V	Sample Sets Incomplete
5 Intermediate Precision	second analyst, different day	V	Sample Sets Incomplete
6 Stability	Stability 1 - 24 hour	V	Sample Sets Incomplete
Data Attached to Selected Test			
Sample Set Metho	vd	S	SSM Status
1 robust_flow_temp_pctorg1			✓
	· · · ·		

Figure 2. The written protocol can be easily transferred to Empower Method Validation Manager.

Individual tests and their associated a were configured, as shown in Figures

Figure 3. Accuracy test configuration. Three s tion levels with three individual preparations time. Levels were entered in the levels table. that samples submitted for accuracy analysis parameters.

Accuracy Parameters

Acquisition Processing and Acceptance Criteria

/idu	ual tes	ts and	their assoc	ciated ad	ceptanc	e criteria		Accuracy Param	eters										X
e cc	onfigur	ed, as	shown in F	igures 3	and 4.			Acquisition Proc	essing and	Acceptance	e Criteria								
e 3. Leve sam met	Accurc Is with vels wer ples su ers.	acy test c three inc e entere bmitted ;	configuration dividual prep d in the leve for accuracy	n. Three s _i parations els table. analysis	pecified ca were injec MVM then match the	oncentra- cted one ensures e defined				iteria: Exa vvels: 80% 100% 120% 4 2	ct	Preparations/L Injections/Prep Injections:	evel:		4				
	-																		
ura	cy Para	meters								<u> </u>	4								
quisi	tion Pro	cessing ar	nd Acceptance	Criteria															
Cor	nponent 1	lype - Sele	ect row to set Ad	ceptance C	riteria									01/	-				
•		Compone	nt Type		Assessed	Field		Significance I	.evel					UK	_	Lance	<u> </u>	Heip	<u> </u>
1	Main Cor	nponent		% Reco	very		0.05												
H																			
Н				_															
H																			
Acc	eptance	Criteria per	r Component Ty	pe			1												
6	Field	Туре	Field Name	e Tar <u>c</u>	et % Ranj	ge LowerLim	iit (LL)	Upper Limit (UL)	Fault on	Target									
1	Accurac	y Result	% Recovery N	1ean 100	00		95.00	105.00	Г	1									
Н																			
Н					_														
Н																			
	entance	Criteria per	r Component Tu		1														
	Level	Field Typ	e Field Name	Target	% Range	Lower Limit		Upper Limit (UL)	Fault on 1	Target									
				-															
								I											
											Figure 4	. Acceptance	e criter	ia for ti	the a	ccuracy	test.	Percei	nt
								Cance		Help	Figure 4 recovery	. Acceptance I was the test	e criter t resul	ria for ta t of inte	the au	ccuracy . The a	test.	Percei ance re	nt ange

Complete sample set methods were constructed and then saved as templates within the validation protocol method (Figure 5).

Figure 5. Sample set method.

0	robust_fl	ow_temp_pctorg	1 in c	lan ro	ot\MVM_study\drug1_assayval\Amlodipine	Assay on INFM-EMPSRV-01 as rootd/	PowerUser -	Sample Set i	Method Editor				
jle	Edit ⊻ier	w <u>H</u> elp											
	2	<u></u>	3	111									
6	Plate/Well	SampleName	lnj Vol (uL)	# of Injs	Function	Method Set / Report Method	Run Time (Minutes)	Level	Sample Preparation	Next Inj. Delay (Minutes)	analyst	Experiment Name	Robustnes
	1:a,1	test inj.	1.0	1	Inject Samples	aceta_robust1	2.00	0%		0.00			Г
	1:a,2	sys prec. 100% std	1.0	6	Inject Standards	aceta_robust1	2.00	100%		0.00			Г
	1:a,3	100% prep	1.0	1	Inject Samples	aceta_robust1	2.00	100%	Preparation 1	0.00		Experiment 1	V
	1:a,4	100% prep	1.0	1	Inject Samples	aceta_robust1	2.00	100%	Preparation 2	0.00		Experiment 1	4
	1:a,5	100% prep	1.0	1	Inject Samples	aceta_robust1	2.00	100%	Preparation 3	0.00		Experiment 1	V
	1:a,6	100% prep	1.0	1	Inject Samples	aceta_robust1	2.00	100%	Preparation 4	0.00		Experiment 1	~
	1:a,7	100% prep	1.0	1	Inject Samples	aceta_robust1	2.00	100%	Preparation 5	0.00		Experiment 1	7
1	1:a,8	100% prep	1.0	1	Inject Samples	aceta_robust1	2.00	100%	Preparation 6	0.00		Experiment 1	v
1					Clear Calibration	aceta_robust1							
)					Calibrate	aceta_robust1							
					Quantitate	aceta_robust1							
2					Equilibrate	aceta_robust2	10.00			0.00			
	1:a,1	test inj.	1.0	1	Inject Samples	aceta_robust2	2.00	0%		0.00			Г
	1:a,2	ref. std. 100%	1.0	6	Inject Standards	aceta_robust2	2.00	100%		0.00		Experiment 3	Г
	1:a,3	100% prep	1.0	1	Inject Samples	aceta_robust2	2.00	100%	Preparation 1	0.00		Experiment 3	v
	1:a,4	100% prep	1.0	1	Inject Samples	aceta_robust2	2.00	100%	Preparation 2	0.00		Experiment 3	V
1	1:a,5	100% prep	1.0	1	Inject Samples	aceta_robust2	2.00	100%	Preparation 3	0.00		Experiment 3	V
3	1:a,6	100% prep	1.0	1	Inject Samples	aceta_robust2	2.00	100%	Preparation 4	0.00		Experiment 3	~
1	1:a,7	100% prep	1.0	1	Inject Samples	aceta_robust2	2.00	100%	Preparation 5	0.00		Experiment 3	v
1	1:a,8	100% prep	1.0	1	Inject Samples	aceta_robust2	2.00	100%	Preparation 6	0.00		Experiment 3	V
1					Clear Calibration	aceta_robust2							
2					Calibrate	aceta_robust2							
					Guantitate	aceta_robust2							
1					Equilibrate	aceta_robust3	10.00			0.00			
	1:a,1	test inj.	1.0	1	Inject Samples	aceta_robust3	2.00	0%		0.00			Г
;	1:a,2	ref. std. 100%	1.0	6	Inject Standards	aceta_robust3	2.00	100%		0.00		Experiment 2	Г
7	1:a,3	100% prep	1.0	1	Inject Samples	aceta_robust3	2.00	100%	Preparation 1	0.00		Experiment 2	V
;	1:a,4	100% prep	1.0	1	Inject Samples	aceta_robust3	2.00	100%	Preparation 2	0.00		Experiment 2	V
3	1:a,5	100% prep	1.0	1	Inject Samples	aceta_robust3	2.00	100%	Preparation 3	0.00		Experiment 2	V
Ì	1:a,6	100% prep	1.0	1	Inject Samples	aceta_robust3	2.00	100%	Preparation 4	0.00		Experiment 2	V
t	1:a,7	100% prep	1.0	1	Inject Samples	aceta_robust3	2.00	100%	Preparation 5	0.00		Experiment 2	V
ł	1:a,8	100% prep	1.0	1	Inject Samples	aceta_robust3	2.00	100%	Preparation 6	0.00		Experiment 2	V
3					Clear Calibration	aceta robust3			·				
4					Calibrate	aceta_robust3							
5					Quantitate	aceta robust3							
-					Sauiltyrata	-	10.00			0.00			

🖉 Validation Protocol - acetaminophen2 in da	n root\MVM_study\drug1_	assayval\Amlo	dipine Ass	ay on INFI	A-EMPSRV-0	l as root	d/PowerUser - \	/alida 🔳 🗖
jile <u>E</u> dit <u>V</u> iew <u>T</u> ools <u>H</u> elp								
Method Classification Compound Type: Drug Product Analytical Method Type: Assay Development Phase: Development Protocol Comments:	Method/Study Validation Prot	Approvals tocol Approval:						
Validation Tests System Precision Approvals/Sign Off	5							
Acquisition Parameters	Processing and Acceptance C Component Type - Select row t	riteria to set Acceptance	e Criteria					
System Precision Required	Component Ty	/pe	1	Assessed Fie	ld		Significance Le	vel
for all Sample Sets	1 Main Component		Area			0.05		
Criteria:	2 Main Component		Retention Tim	ie		0.05		
Exact -	3 Main Component		USP Tailing			0.05		
	4 Main Component		USP Plate Cor	unt		0.05		
Vials/Sample Set: 1	Accentance Criteria per Compo	ment Tune						
	Field Type	Field Nan	ne Ta	arget % Ra	ange Lower	Limit (LL)	Upper Limit (UL)	Fault on Target
Injections/Vial: 6	1 System Precision Result	Assessed Field	% RSD	-	-		2.000000	
Injections: 6								
	Accentance Criteria per Compr	nent Tupe per Le	vel				1	
	Level Field Type	Field Name	Target	% Range	Lower Limit	(LL) (Jpper Limit (UL)	Fault on Target
			-	2				

Since the validation protocol called for method suitability parameters to be met by each analysis, system precision requirements were also configured (Figure 6).

Figure 6. System precision parameters. In this protocol, the % RSD of peak area must be no more than 2%.

During the process of test configuration and sample set method construction, errors were automatically caught by MVM, as indicated by a red X in the validation protocol window. Using the update status button and responding to error messages from the message center effectively guides all troubleshooting activity (Figure 7).

🐼 Validation Protocol - acetaminophen2 in dan	root\WVM_study\drue1_assayval\An	nlodipine Assay or	n INFM-EMPSRV-01 as roo 🔳 🗖 🔀
<u>File Edit View Tools H</u> elp	Update status button		
Method Classification Compound Type: Drug Product Analytical Method Type: Assay Development Phase: Development Protocol Comments:	Method/Study Approvals Validation Protocol Approval:		
Validation Tests System Precision Approvals/Sign Offs Validation Tests			
🚳 Test Name	Test Description	Required	Test Status
1 Robustness	Robustness 1. 4 factors	v	Sample Sets Incomplete
2 Repeatability	Repeatability 1	V	Sample Sets Incomplete
3 Linearity	Linearity 1	V	SS Methods Incomplete
4 Accuracy	Accuracy 1	V	SS Methods Incomplete
5 Intermediate Precision	second analyst, different day		Sample Sets Incomplete
6 Stability	Stability 1 - 24 hour	V	Sample Sets Incomplete
Data Attached to Selected Test	nod		SSM Status
1 acc_lin_5pt_assay_ds	The red X indicates an error set method that is inconsiste validation test configuration.	in the sample nt with the	→ ¥.
INFM-EMPSRV-01 - Message Center			
Eile <u>Vi</u> ew <u>H</u> elp			
S Project		Message	
1 dan rootWV/M_study/drug1_assayval/Amlodipine Assay Test Robustr	ness 1. 4 factors: Either the Robustness test field is not	checked or the level does n	ot match the level specified in the configuration parameters.
2 plan rootVMV/M_study/drug1_assayval/Amlodipine Assay Test Linearit	y 1: The number of preparations for Level '80%' does not	t match the number specifie	d in the configuration parameters.
▲ All A General & Acquisition & Security & Processing /	1		•
For Help, press F1			

Figure 7. Linearity sample set method error caught by Empower 2 MVM Software. The message center indicated a problem, which was easily resolved. MVM ensured that all sample set methods were consistent with their respective test configurations. An earlier error for a robustness test configuration is also visible.

The validation protocol method was saved within a validation template project. Next, a validation working project was started and a new study was initiated based on the validation protocol method template.

The validation manager window lists the test configurations and acceptance criteria for the validation study. Additional functionality includes indicators that show test status and required approval (Figure 8). Since complete sample set methods are contained in the validation protocol method, the study can now be executed. Standards and samples were prepared then analyzed on the ACQUITY UPLC System as the previously established sample set methods.

🕑 v	alidation Study - acetaminophen3 in	dan ro	oot\MVM_study	y\drug	1_assa	yval\	Amlodipine As	ssay on INF	M-EMP	SRV-01	as ro (
File	Eait view Loois Help	0					a 🗛 📣			6		
Ľ	- 🖷 👯 🗿 🔊 刘		😌 📕 🖁	II Ü) (3 🥝 段					
A	lethod Classification Compound Type: Drug Product inalytical Method Type: Assay Development Phase: Development Protocol Comments:			Method. Validati Valid Valid	/Study Aj on Protoc lation Pro Overall S ation Stu	pprov col Ap tocol (tudy) dy Ap	als proval: Name: acetamin Status: Study Inc proval:	iophen3 complete				
Va Va	lidation Tests System Precision Approvals/S lidation Tests	ign Offs										
65	Test Name		Test Description		Requir	ed	Test Statu	s	VR Stat	us 🛛	VR Sign Off(s)
1	Robustness	Robust	ness 1. 3 factors		~		Sample Sets Inco	mplete				
2	Repeatability	Repeat	ability 1		V		Sample Sets Inco	mplete				
3	Linearity	Linearit	y 1		Sample Sets Incomplete			mplete				
4	Accuracy	Accura	cy 1				Sample Sets Inco	mplete				
5	Intermediate Precision	second	analyst, different	day	•		Sample Sets Inco	mplete				
6	Stability	Stability	1 - 24 hour		•		Sample Sets Inco	mplete				
Da	ta Attached to Selected Test	I						I				
66	Sample Set Method	SSM ld	SSM Status	SSM A	oproval	SS Id	SS Status	SS Approval	RS ld	RS Stat	tus RSS	ign C
1	robust_flow_temp_pctorg		>									
F			Green check i results consist	indicate: tent with	s a sam n the val	ole se idatio	et method that w in test configurat	ill yield tion.				
<	ļ		•				•					>
•												
· _						_						

Figure 8. The green check mark in this validation manager window indicates that the sample set method is consistent with the user-configured test criteria.

RESULTS

Robustness

Robustness was evaluated using a 1/2 fractional factorial experimental design. The parameters assessed were flow rate, percent organic in the mobile phase, and column temperature (Table 2). Because the sample preparation procedure of this method is direct from the United States Pharmacopeia , only selected instrumental parameters were evaluated. The acceptance criteria for the test were:

- The amount of acetaminophen determined must fall within 5% of the target value.
- 2) The %RSD of the amount must be no more than 3%.

A parameter that fails these criteria will need to be tightly controlled when performing the assay.

Experiment #	Column temperature °C	Percent Organic	Flow rate mL/min
1	37	8	0.750
2	43	8	0.550
3	37	12	0.550
4	43	12	0.750

Table 2. Experimental design of robustness from MVM.

The results of the robustness testing indicate that all three factors – percent organic, flow rate, and column temperature – had statistically significant effects on the determination of acetaminophen by this method. Referring to the effects plot in the validation result review window in Figure 9, varying the percent organic by $\pm 2\%$, the temperature by ± 3 °C, and the flow rate by ± 0.1 mL/min, produced a 1%, 5%, and 10% effect on the assayed acetaminophen amount respectively.

In this case, robustness was evaluated for only the primary effects of the three factors with no consideration given to interaction. However, additional factors and the assessment of possible interactions between them, can all be performed easily and the results analyzed with MVM's powerful statistical techniques with a minimum of effort on the part of the validation analyst.

3	🖹 acetaminophen2 in dan root\WVM_study\drug1	_as	sayval	Amlodipine	e Assay on INI	M-1	MPSRV-01	s root	d/PowerU	lser - Validati	n Review -	[Robustr	iess]			ואן
1	Ele View Navigate Help															
	7 F 🗞 🥙 🖉 🖉	_														
	■ Robustness ● Study - acetaminophen2 ● Total Description: Robustness 1. 3 factors ● Study - acetaminophen Amount ACQUITY TUV CI ● Study - acetaminophen Amount ACQUITY TUV CIA ● Study - acetaminophen Amount ACQUITY TUV CIA ● Study - acetaminophen Area ACQUITY TUV CIA ● Test Description: Robustness 1. 3 factors ● Test Description: Robustness 1. 3 factors ● Test Description: Problem Area ACQUITY TUV CIA ● acetaminophen Area ACQUITY TUV CIA ● acetaminophen Plate Flating ACQUITY TUV CIA ● acetaminophen USP Flate Count ACQUITY TUV	-	Factors & Interactions	C- B- A- -0.0011	-0.0010 Variance Plot	-0 -0	.0009	0.0008	-0.0	1007 -0.0 Effec end Plot /	006 -(8	0.0005	-0.0004	-0.0003	-0.0002	
		6	Visible	Validation Result Id	Test Descrip	tion	Compone	nt Type	Compor	nent Proc	essing Codes	Faults	Experiment	s Points/Experiment	Group By	Ass
L		1		5001	Robustness 1. 3	3 fac	tors Main Con	ponent	acetamin	ophen MV28 N	V16 MV69 MV	75 🔽		4 6	Experiment Name	Amo
		F														
L																
L		<				_	-									>
L		1	I ▶ IV E	ffects Plot 🖌	Variance Plot	(Ha	lif Normal Pro	babilit	/ Plot 🔏 Tre	end Plot <u>λ</u> Robu	stness Resu	ult <u>á</u> Test I	Effects 🔏 Alt	IOVA 🖌 Data 🖌 Peal	Result /	
L		8	Factor	Source	SS	DF	MS	1	-Ratio	F-Ratio Reference	e p-Value	Variance C	component 9	6 Variance Component	Variance Comp	onent
L		1	A	pct_org_mp	3.824533e-007	1	3.824533e-00	7 21	90.830933	6.6078	1 0.000000		0.000000	1.180284		0.0001
		2	в	col_temp	6.048435e-006	1	6.048435e-00	5 346	47.624652	6.6078	1 0.000000		0.000001	19.519132		0.0007
		3	с	flow_rate	2.430504e-005	1	2.430504e-00	5 1392	28.100284	6.6078	1 0.000000		0.000002	78.609548		0.0014
								_			_					_
	< >	<					ш)				>
	landu	14	I ► I <u>\</u> R	obustness R	lesult à Test Ef	ect	s 🕻 ANOVA 🥻	Data 🔏	Peak Res	uit /	covintion Dob	utpace 1 - 3	factors	Studu scataminani	2002	_
L.S.	cauy	_			pu pu	mpu	nenciacetallilli	prieff		Test De	scriptionskubt	15010551.3	ractors	prody acecaninopi	10112	11.

Figure 9. Validation test result review window. If the drug name appears in bold, red type, this indicates an out of specification result. Using the tabs of the review screen, the exact nature of the out-of-specification result can be quickly determined.

Repeatability

Repeatability (intra-assay precision) was tested by analyzing six individual sample preparations according to method conditions. The resulting 0.13% RSD for amount easily fell within the acceptance criterion of %RSD ≤2.0%, demonstrating that this assay is highly repeatable (Figure 10).

This repeatability result was used in the intermediate precision determination and as the initial time point for the solution stability test. MVM automatically consolidates test result calculations from separate sample set methods.

🕀 acetaminophen2 in dan root\WVM_stu	dy\	.drug1_a	ssayval	Amlodipine	Assay on INFM	I-EMP	SRV-01 as r	ootd/PowerU	ser - Va	lidation R	eview - [Repeate	ability]		
<u>File View N</u> avigate <u>H</u> elp														
Constant Study - acetaminophen2 Study - acetaminophen2 System Precision W Study - acetaminophen Amount ACQL System Precision W Study - acetaminophen2 Or Study - acetaminophen2 Or Study - acetaminophen2 Or Study - acetaminophen2		0.64 1 June 26.0 June 27.0		٠		•		٠		٠		٠	۰	
ir; acetaminophen Area ACQUIT ir; acetaminophen Retention Tim		().5	1	1.5	2	2.5	3	3.5 Run Numk	4 ier	4.5	5	5.5 6	6.5
ij acetaminophen USP Tailing A			•											•
	1	🕨 🕻 Rej	peatabilit	<u>y Plot</u>), Trend	Plot /	Rep	eatability res	ult						
	6	Assesse	d Field	Assessed Field Units	Assessed Field Mean	a As	sessed Field SD	Assessed Fiel % RSD	d ^{Asse}	essed Field Mean td Error	Assessed Field Mean Cl	Assessed Field Mean LCL	Assessed Field Mean UCL	Assessed F Skew
	1	Amount			0.01009)4	0.000013	* 0.1309	01	0.000005	0.000014	0.010080	0.010107	-0.46
	<											ш		>
	. ∎	Rep 1	peatabili	v Plot 🔏 Trend	Plot & Repeata	bility I	Result 🔏 Lev	el Summary 🖌	ANOVA	🖌 Data 🔏 P	eak Result 🖌			
	60	Result Id	Channel	ld Result Id	Component	Level	Data Faults	Retention Time (min)	X Value	X Value Field Type	Normalized Weight	Assessed Field	Assessed Field Value	
	1	3226	286	3248	acetaminophen	100%		0.618			1.000000	Amount	0.010100	
	2	3229	298	31 3248	acetaminophen	100%		0.619			1.000000	Amount	0.010075	
	3	3232	298	34 3248	acetaminophen	100%	Γ	0.620			1.000000	Amount	0.010091	
	4	3235	298	37 3248	acetaminophen	100%		0.619			1.000000	Amount	0.010082	
	5	3238	299	90 3248	acetaminophen	100%		0.618			1.000000	Amount	0.010107	
	6	3241	299	3 3248	acetaminophen	100%		0.620			1.000000	Amount	0.010106	
< >														
Peady	14	I ▶ I <u>\ Re</u> p	peatabilit	y Result 🔏 Lev	Components	ANOV	<u>∖}Data ∦</u> P	eak Result 🖌	Tect Dor	cription Per	eatability 1	Studenser	ataminonben?	
Noday	_				Componenca	acocam	nopriori		Juest Des	спраонлер	Sacability 1	Jocadian	scammoprienz	

Figure 10. Repeatability test in the validation result review window.

Intermediate precision

Intermediate precision (ruggedness, inter-assay precision) was evaluated for a different analyst, on a different day, on a different instrument and column. Six individual sample preparations were analyzed according to method conditions. Results were compared with the repeatability determination. A difference of no more than 3.0% in the amount of acetaminophen between the two analysts was an acceptable result. The resulting 2.6% difference demonstrates the ruggedness of this assay (Figure 11).

🏶 acetaminophen2 in dan root\WVM_study\dru	g1_a	issayvalV	mlodip	ine A	ssay on INI	M-EMPSRV	-01	as rootd/Pow	verUser - Va	lidatio	n Review - [ntermediate Pro	ecision]	
<u>File V</u> iew <u>N</u> avigate <u>H</u> elp														
707 7 7 2 2	_													
Constant Study - acetaminophen2 Study - acetaminophen2 Sudy - acetaminophen2 Sudy - acetaminophen Amount ACQUITY TUV System Precision Sudy - acetaminophen2 Sudy - acetaminophen2 Sudy - acetaminophen2		a 0.64 iii 0.62 iiii 0.62 iiii 0.60	٠		٠	٠	•	٠	•	•	٠	ø	• •	•
acetaminophen Area ACQUITY TUV CP i; acetaminophen Retention Time ACQUI			1		2	3	4	5		lumber	8	9	10 1	12
v; acetaminophen USP Tailing ACQUITY v; acetaminophen USP Plate Count ACQU			•											Þ
i; acetaminophen Area ACQUITY TUV Cŀ		▶ 1 Interr	nediate	Precis	sion Plot λ1	rend Plot 🖊		Intermediate	precision res	ult				
ividential action ividential action ividential action ividential action	6	ntion Time Mean	X Value Mean	Ass	essed Field	Assessed Fie Mean	eld	Assessed Fiel SD	A A Sessed	Field)	Assessed Fiel Mean Std Error	H Assessed Field Mean Cl	Assessed Fiel Mean LCL	d Assessed Field Mean UCL
	1	0.619		Am	ount	0.010	094	0.00001	3	0.13	0.00000	IS 0.00001-	4 0.0100	30 0.010107
	2	0.622		Am	ount	0.009	838	0.00026	39	2.74	0.00011	0 0.00028	3 0.0095	55 0.010120
	नि	► \ Interr	nediate	Precis	sion Plot 🖌 1	rend Plot 🖌	Inter	rmediate Preci	sion Result	λ Expe	iment Summ	ary 🖌 ANOVA 🔏 D:	ata 🖌 Peak Resi	ult 🕻 Supportable Es
	66	Compo	inent I	_evel	Experiment Group	Data Faults	Proc	cessing Codes	Retention Time (min)	X Val	ie X Value Field Type	Normalized Weight	Assessed Field	Assessed Field Assessed Field
	1	8 acetamir	nophen	100%	1				0.618			1.000000	Amount	0.010100
	2	8 acetamir	nophen	100%	1				0.619			1.000000	Amount	0.010075
	3	8 acetamir	nophen	100%	1				0.620			1.000000	Amount	0.010091
	4	8 acetamir	ophen	100%	1				0.619	·		1.000000	Amount	0.010082
	5	8 acetamir	nophen	100%	1				0.618		_	1.000000	Amount	0.010107
	6	8 acetamir	nophen	100%	1				0.620	<u> </u>		1.000000	Amount	0.010106
	1	8 acetamir	nophen	100%	2				0.620			1.000000	Amount	0.009494
	8	8 acetamir	nophen	100%	2				0.621		_	1.000000	Amount	0.010041
	10	o acetamir	ophen	100%	2				0.621			1.000000	Amount	0.010038
	11	e acetamii	ophen	100%	2				0.622		_	1.000000	Amount	0.009974
	-				-	_	L		0.024					×
<	<	Interr	nediate	Precis	sion Result	Experimer	nt Su	ummary 🖌 ANC	VA Data 🖌	Peak F	lesult 🖌 Supp	ortable Estimation	1	>
Ready					Componen	t:acetaminoph	nen		Test Des	cription	second analyst,	different day St	udy:acetaminophe	n2 //

Figure 11. Intermediate precision result shown in the validation result review window.

Accuracy

Accuracy was assessed by analyzing triplicate preparations of mobile phase spiked with acetaminophen RS at 80, 90, 100, 110, and 120% of the target concentration of the method (0.01 mg/mL). The recovery result from the spiked acetaminophen ranged from 99 to 101% and fell within the 95 to 105% acceptance range. The method is very accurate for the range tested (Figure 12).

🕀 acetaminophen2 in dan root\MVM_stu	ıdy\d	lrug1_assay	val\Amlodipi	ne Ass	ay on INF	M-EMPSRV-	01 as roo	td/Power	User - V	alidation Re	view - [Accu	racy]			_ 0	
<u>File Vi</u> ew <u>N</u> avigate <u>H</u> elp																
Accuracy Study - acetaminophen2 Study - acetaminophen2 System Precision W Study - acetaminophen % Recovery A System Precision W Study - acetaminophen2 Test Description: Accuracy 1 Ta acetaminophen Area ACQUIT	110.00 0 0 0 0 0 0 0 0 0 0 0 0							, ⊂ 95 10		3 CO 105 110					2 0 125	
- <u>i</u> ; acetaminophen Retention Tim			-1						Leve	4						_
$\vec{y_i}$ acetaminophen USP Plate Co			Diet (Trees	Dist (<u>></u>
		▶ <u> </u> {Accurac	V Plot & Trend	Plot /												=
	6	X Value Validation Tar <u>c</u>	X Value et Lower Rang	e Upp	Value ⁴ er Range	% Recovery Mean	% Recove SD	y % Rec % F	covery RSD	% Recovery Mean Std Error	% Recovery Mean Cl	% Recovery Mean LCL	% Reco Mea UCL	very % Re n Sł	covery æw	Ca Valida
	1		0.00800	0 1	0.012000	100.24	0.5141	20 0.	512865	0.132745	0.284710	99.96	1	00.53 -0	.861692	_
	<	N Accurac	v Plot I Trond	Plot)	Accuracy	Pocult (Lo	ol Summe	N LANO	(A / Doto	/ Pook Poo	ult 1		_		_	>
		Validation	YFIOL A HEIIG	FIULA	Accuracy		Per Sullinia	IT A ANON		A Feak Res	uit <u>7</u>	1				
	66	Result Id	Component	Level	Data Faults	Processing	Codes Rei	(min)	X Value	Field Type	Normalized Weig	ht Calculated X	. Value	% Recovery	% Bias	-
	1	5051	acetaminophen	100%	Γ			0.619	0.010000) Amount	1.0000	00 0.0	09992	99.92	-0.07882	9
	2	5051	acetaminophen	100%				0.619	0.010000) Amount	1.0000	00 00	010023	100.23	0.22517	1
	3	5051	acetaminophen	100%				0.620	0.010000) Amount	1.0000	00 0.0	010017	100.17	0.17488	8
	4	5051	acetaminophen	110%				0.620	0.011000) Amount	1.0000	00 0.0	011049	100.45	0.44787	9
	6	5051	acetaminophen	110%				0.620	0.011000	Amount	1.0000		J11015	100.13	0.13469	4
	7	5051	acetaminophen	120%		-		0.620	0.012000	Amount	1.0000		112083	100.76	0.76224	8
	8	5051	acetaminophen	120%	, 			0.620	0.012000	Amount	1.0000		112003	100.03	0.77308	3
	9	5051	acetaminophen	120%	Г	-		0.619	0.012000) Amount	1.0000	00 0.0	012059	100.49	0.49415	1
	10	5051	acetaminophen	80%	Г			0.619	0.008000) Amount	1.0000	00 0.0	008042	100.53	0.52913	7
	11	5051	acetaminophen	80%	Г			0.618	0.008000) Amount	1.0000	00 0.0	008050	100.63	0.63047	2
	12	5051	acetaminophen	80%	Г			0.619	0.008000) Amount	1.0000	00 0.0	08059	100.74	0.73819	8
2	<	•														>
Dearly	141	Accurac	y Result 🔏 Lev	el Sun	Component	IOVA) Data	A Peak R	esult /	Tect Dr	scription: Accu	racy 1	Chud	viacetor	pipophen?		
reauy					Component	.acetaminophi	50		Jiest De	SCHPOOLSACCO	acy 1	Jotua	y.acecan	mophenz		

Figure 12. Accuracy validation result review window.

Linearity

Linearity was evaluated from the same experiment as the accuracy test. The results were linear with slope = 5.47×10^6 , R² = 0.999, and a y-intercept of -720.3. The method is linear within the range tested (Figure 13).



Figure 13. Linearity result shown in the validation result review window.

Stability

Stability was evaluated by the analysis of the repeatability sample preparations (N=6) after 24 hours at room temperature. The repeatability results were used as the time zero condition and were automatically used in the stability data processing. As shown in the validation results, acetaminophen sample preparations are stable for at least 24 hours (Figure 14).

🗑 acetaminophen2 in dan root\WVM_study\drug1_assayval\Amlodipine Assay on INFM-EMPSRV-01 as rootd/PowerUser - Validation Review - [Stability]														
Eile View Navigate Help														
Study - acetaminophen2 Study - acetaminophen2 Study - acetaminophen Amount ACQUITY TUV ChA Cacetaminophen Amount ACQUITY TUV ChA System Precision Study - acetaminophen Amount ACQUITY TUV ChA Study - acetaminophen2 Study - acetaminophen Area ACQUITY TUV ChA	-	0.011		00 2.00	4.00	6.00	8.00 10	1.00 12.00 Hours	, , , , , , , , , , , , , , , , , , ,	, , , , , , , , , , , , , , , , , , ,	, , , , , , , , , , , , , , , , , , ,	22.00	24.00	
acetaminophen USP Tailing ACQUITY TUV ChA														
17 acetaminophen USP Plate Count ACQUITY TUV ChA 17 acetaminophen Area ACQUITY TUV ChA 17 acetaminophen Areitoriton Tima ACQUITY TUV ChA 17 acetaminophen Berbrino Tima ACQUITY TUV ChA 17 acetaminophen USP Tailing ACQUITY TUV ChA 17 acetaminophen USP Tailing ACQUITY TUV ChA 17 acetaminophen USP Plate Count ACQUITY TUV ChA		Stability Plot & Trend Plot												
	6	Test Des	cription C	omponent Type	Component	Faults	Points/Group	Group By	Assessed Field	Assessed Field Mean	Assessed Fiel SD	d Asses %	sed Field RSD	
	1	Stability 1	- 24 hour 🛛 N	ain Component	acetaminoph	en 🗌	6	Storage Time	Amount	0.01009	4 0.0000 [,]	13	0.130901	
	2	Stability 1	- 24 hour 🛛 N	ain Component	acetaminoph	en 🗌	6	Storage Time	Amount	0.01008	2 0.0000 ⁴	11	0.110302	
													>	
		🕨 🚺 Stal	oility Plot 🖌	Trend Plot λ St	ability Resu	It 🖌 Stora	ge Summary	🕻 ANOVA 🔏 E)ata 🔏 Peak Re	sult 🕻 Relative f	Peaks /			
	69	Result Id	Validation Result ld	Component	Storage Condition	Storage Time	Storage Time Units	Data Faults	Retention Time (min)	Assessed Field	Assessed Field Value	Area (µ∀*sec)	% Area e	
	1	3226	5011	acetaminophen	Reference	0.000	Hours		0.618	Amount	0.010100	53694	100.00	
	2	3229	5011	acetaminophen	Reference	0.000	Hours		0.619	Amount	0.010075	53558	100.00	
	3	3232	5011	acetaminophen	Reference	0.000	Hours		0.620	Amount	0.010091	53646	100.00	
	4	3235	5011	acetaminophen	Reference	0.000	Hours	Γ	0.619	Amount	0.010082	53599	100.00	
	5	3238	5011	acetaminophen	Reference	0.000	Hours	Γ	0.618	Amount	0.010107	53730	100.00	
	6	3241	5011	acetaminophen	Reference	0.000	Hours	Γ	0.620	Amount	0.010106	53726	100.00	
	-						1	1					>	
]	1	► 🔪 Stat	ility Result	🖌 Storage Sun	nmary 🔏 AN	OVA Dat	ta 🖌 Peak Re:	sult 🖌 Relativ	e Peaks /				-	
Ready				Component:ac	etaminophen		Te	st Description:	Stability 1 - 24 ho	ur St	udy:acetaminophe	n2		

Figure 14. The consolidated results of two separate sample sets are presented in the stability validation test result review window.

Validation summary

The status and final results for each of the validation tests was clearly displayed in the validation manager window. The green checks indicated tests with acceptable validation results, while the yellow triangle flagged robustness test results that fell outside the acceptance range (Figure 15).

The method for the assay of acetaminophen was analyzed for robustness, repeatability, intermediate precision, accuracy, linearity, and solution stability. This assay was found to be linear, accurate, repeatable, and to be accurately and precisely performed by more than one analyst. Additionally, samples prepared following the method procedure were documented as stable for 24 hours. From the robustness testing, altering the column temperature and flow rate was found to significantly affect the accuracy and precision of the method. The method will be revised to clearly state the need to control these two factors.

🖉 v	alidation Study - acetaminophen2 in	dan root\MVM_s	tudy\drug1_	assayval\Am	nlodipine Ass	ay on INFM	-EMPS	RV-01 as ro	otd/Po 🔳 🗖 🚺				
Eile Edit View Iools Help													
A	lethod Classification Compound Type: Drug Product unalytical Method Type: Assay Development Phase: Development Protocol Comments:		Method/Study Approvals Validation Protocol Approval: Validation Protocol Name: acetaminophen2 Overall Study Status: Study Complete Validation Study Approval:										
Va	Validation Tests System Precision Approvals/Sign Offs												
Va	lidation Tests												
6	Test Name	Test Desc	ription	Required	Test Status		VR Status		VR Sign Off(s)				
1	Robustness	Robustness 1, 3 f	actors	▼	Test Complete		Δ						
2	Repeatability	Repeatability 1		V	Test Complete		✓						
3	Linearity	Linearity 1			Test Complete		✓						
4	Accuracy			Test Complete		<u> </u>							
5	Intermediate Precision	ferent day		Test Complete		V							
6	Stability	,		Test Complete		<u> </u>							
Da	ta Attached to Selected Test												
6	Sample Set Method	SSM Id SSM State	us SSM Appi	roval SS ld	SS Status	SS Approval	RS ld	RS Status	RS Sign Off(s)				
1	intermediate_prec_exp1	3374 🖌		3436	V		3658	V					
2	repeatability_assay_tablet	2733		2734	V		3211 🗸 🗸						

Figure 15. The validation manager window shows that validation is complete.

CONCLUSION

Empower 2 Method Validation Manager Software effectively streamlines the validation process and integrates smoothly into the validation workflow of the compliant laboratory.

Some of the benefits from the use of MVM are:

- Regulatory compliance: Empower 2 MVM Software easily meets all of the regulatory needs of the compliant laboratory.
- Straight-forward validation troubleshooting: The update tool/message center provides an application-directed, timeefficient troubleshooting process, reducing the time required to get the validation back on track.
- Data traceability: Out of specification results are clearly indicated and subsequent investigations are facilitated by the self-contained, completely traceable data management capability of the MVM.
- **Reduction of supervisory review:** The onus of supervisory review is reduced using MVM, enabling rapid progression in the validation workflow. Potentially error-prone steps such as processing, calculation, and overall data management are all eliminated with the automatic, self-contained design of MVM. The need for any additional third party software packages is also eliminated.
- Validation consistency: The ability to create project and sample set method templates ensures consistency of validation protocols with the guidance documents of the laboratory. This reduces errors in the execution of the protocols and increases confidence in the data acquired and the results obtained.

MVM not only effectively organizes and manages the performance of a method validation, it also delivers inarguable confidence in its results. Coupling Empower 2 Method Validation Manager Software to the ACQUITY UPLC System provides an unparalleled solution to the validation needs of a laboratory.

Waters THE SCIENCE OF WHAT'S POSSIBLE.™

Waters and ACQUITY UPLC are registered trademarks of Waters Corporation. The Science of What's Possible and Empower are trademarks of Waters Corporation. All other trademarks are property of their respective owners.

©2007 Waters Corporation Printed in the USA November 2007 720002401EN AG-PDF Waters Corporation 34 Maple Street Milford, MA 01757 U.S.A. T: 1 508 478 2000 F: 1 508 872 1990 www.waters.com

